Interferon News and Research

RSS

The immune system's hidden talents

Half of the immune system has a hidden talent, researchers at Washington University School of Medicine in St. Louis have discovered.

27 Jan 2009

Bristol-Myers Squibb and ZymoGenetics to collaborate on hepatitis C compound

Bristol-Myers Squibb and ZymoGenetics, Inc. have announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its related development program.

12 Jan 2009

A new mechanism regulates type I interferon production in white blood cells

A study from a team of researchers led by Dr. Andrew P. Makrigiannis, Director of the Molecular Immunology Research Unit at the IRCM, has identified a new mechanism regulating interferon production.

12 Jan 2009

New genetic markers for ulcerative colitis could lead to treatment

An international consortium of researchers, including major contribution from a team led by Dr. John D. Rioux, a professor of medicine at the Université de Montréal and the Montreal Heart Institute, has identified genetic markers associated with risk for ulcerative colitis.

8 Jan 2009

Active Hexose Correlated Compound shown to enhances immune system by increasing production of key dendritic cells

A recently published study in Nutrition and Cancer (60(5), 643-651) by researchers at Kansai Medical University in Osaka, Japan has shown that AHCC (Active Hexose Correlated Compound) enhances immune function by increasing the number of dendritic cells (DCs).

6 Jan 2009

Discovery of new genetic markers for ulcerative colitis

An international team led by University of Pittsburgh School of Medicine researchers has identified genetic markers associated with risk for ulcerative colitis.

5 Jan 2009

May hepatic granulomas be part of the histological spectrum of chronic hepatitis C?

While older large series of patients with hepatic granulomas have found sarcoidosis and tuberculosis to be the most common causes of hepatic granulomas, recent works have noted some patients with chronic hepatic C and hepatic granulomas and no other obvious associations.

30 Dec 2008

New anti-tumor gene called SARI

Researchers from Virginia Commonwealth University have identified a new anti-tumor gene called SARI that can interact with and suppress a key protein that is overexpressed in 90 percent of human cancers.

16 Dec 2008

UK kidney cancer patients face toxic, out-dated treatments with little hope of change

Leading oncologist Professor Tim Eisen has expressed concerns that patients with advanced kidney cancer could be condemned to toxic, barely effective, 20 year-old treatments because the National Institute for Health and Clinical Excellence (NICE) is likely to rule out using all four of the new treatments it has assessed.

10 Dec 2008

Hep C treatment pegylated interferon reduces the virus but liver damage continues

Treating patients who have chronic hepatitis C and advanced liver disease with long-term pegylated interferon significantly decreased their liver enzymes, viral levels and liver inflammation, but the treatment did not slow or prevent the progression of serious liver disease, a study finds.

10 Dec 2008

Hep C treatment peginterferon reduces the virus but liver damage continues

5 Dec 2008

Interferon as long-term treatment for hepatitis C not effective

Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, UT Southwestern Medical Center researchers and their colleagues from nine other institutions have found in a multicenter study.

5 Dec 2008

Interferon needed for cells to 'remember' how to defeat a virus

Scientists at UT Southwestern Medical Center have determined that the immune-system protein interferon plays a key role in "teaching" the immune system how to fight off repeated infections of the same virus.

3 Dec 2008

Anadys Pharmaceuticals receives fast track for ANA598 treatment of chronic hepatitis C virus

Anadys Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ANA598 for the treatment of chronic hepatitis C virus (HCV) infection. ANA598 is Anadys' investigational hepatitis C non-nucleoside polymerase inhibitor.

1 Dec 2008

Soviet-developed immune formula boosts immune activity

A recent study on an American-made, Soviet-developed immune formula shows the product has a significant effect on immune function.

19 Nov 2008

Interferon eliminates specific causes of some viruses in heart failure patients, improving clinical outcomes

Giving interferon to heart failure patients with evidence of a chronic viral infection safely eliminated two viruses from their systems and reduced levels of a third virus.

11 Nov 2008

Interferon beta treatment success for multiple sclerosis shown with MRI

Regular magnetic resonance imaging (MRI) evaluations show that only about half of patients with multiple sclerosis achieve and sustain a response to treatment with interferon beta over three years, according to a study posted online today that will appear in the January 2009 print issue of Archives of Neurology.

11 Nov 2008

H5N1 protein hides in tiny tubules

A protein found in the virulent avian influenza virus strain called H5N1 forms tiny tubules in which it "hides" the pieces of double-stranded RNA formed during viral infection, which otherwise would prompt an antiviral immune response from infected cells, said Baylor College of Medicine researchers in an online report in the journal Nature.

6 Nov 2008

New therapeutic target for inflammatory disorders

Researchers at Hospital for Special Surgery have identified a potential new therapeutic target that could be used to treat inflammatory disorders, such as rheumatoid arthritis.